The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Clinical Roundup

Cancer drug targets uncovered using base editing and chemical proteomics

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

A team at Scripps Research and the Broad Institute of Harvard and MIT has discovered a new method to hone in on new drug targets most likely to impact multiple cancers.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

In Brief

Fred Hutch announces eight recipients of 2025 Dr. Eddie Méndez Scholar Award

2025 Dr. Eddie Méndez Scholar Award Recipients, top row left to right: Caitlin Cornell, PhD, Elizabeth Kaweesa, PhD, Leandro Fernández-García, PhD, Almudena Chaves Pérez, PhD. Bottom row left to right: Luis Cedeño-Rosario, PhD, Nicole Halmai, PhD, Megan E. Meuser, PhD, Sarah Elisabeth Pierce, PhD.  Fred Hutch Cancer Center has announced eight recipients of the 2025 Dr. Eddie Méndez Scholar Award. 
In Brief

Swim Across America grants $900,000 toward gene editing innovation

Joseph FraiettaPietro GenoveseSwim Across America, the nonprofit funding innovative clinical trials and patient-centered programs for cancer, awarded $450,000 grants to two of its beneficiaries, Alliance for Cancer Gene Therapy and Dana-Farber Cancer Institute, to support the work of novel gene and base editing techniques used in advanced cancer research, including targeted therapies, immunotherapies, and cellular therapies. 
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account